ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Outcomes of Kidney Transplant Recipients with Covid-19 in Singapore Treated with Sotrovimab in the Era of the Delta Variant

M. R. D'Costa1, H. K. Sran1, E. Wong1, Z. Chang2, Y. Chua2, J. Somani3, L. Lum3, A. Vathsala1

1National University Centre for Organ Transplantation, National University Hospital, Singapore, Singapore, 2Medicine, National University Hospital, Singapore, Singapore, 3Infectious Diseases, National University Hospital, Singapore, Singapore

Meeting: 2022 American Transplant Congress

Abstract number: 696

Keywords: COVID-19, Kidney transplantation

Topic: Clinical Science » Infection Disease » 24 - All Infections (Excluding Kidney & Viral Hepatitis)

Session Information

Session Name: All Infections (Excluding Kidney & Viral Hepatitis) I

Session Type: Poster Abstract

Date: Saturday, June 4, 2022

Session Time: 5:30pm-7:00pm

 Presentation Time: 5:30pm-7:00pm

Location: Hynes Halls C & D

*Purpose: Kidney transplant recipients (KTRs) are at higher risk for severe COVID-19 caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Sotrovimab decreases the risk of disease progression in the general population, but efficacy and safety in KTRs is unknown. Herein, we describe our experience in treating COVID-19 infected KTRs with sotrovimab.

*Methods: We performed a retrospective, single-center cohort study of KTRs diagnosed with COVID-19 by polymerase chain reaction from 07/15/21-11/30/21. KTRs with COVID-19 were admitted to the hospital to expedite evaluation and treatment. KTRs with COVID-19 were eligible for sotrovimab if they 1) were not requiring oxygen at admission, 2) were unvaccinated or if SARS-CoV-2 spike antibody (SAb) after vaccination was <100 U/mL, and 3) duration of symptoms/day of illness (DOI) was ≤7 days. COVID-19 disease requiring oxygen therapy was treated with remdesevir + dexamethasone. Immunomodulator therapy (baricitinib or tocilizimab) was given for rapidly progressive disease requiring high-flow oxygen or ICU care. Baseline characteristics, treatments, and outcomes including oxygen supplementation, ICU admission, and mortality were manually abstracted and evaluated.

*Results: In all, 36 KTRs were diagnosed with COVID-19 – mean age 59 years, 72% male, 67% Chinese, 64% diabetic and 17% obese; 72% were deceased donor and 28% were living donor KTRs presenting a mean 11 years from transplant. The majority (69%) were vaccinated with ≥2 doses of mRNA-based SARS-CoV-2 vaccines, 22% received 3 doses, and 15% were unvaccinated. Among KTRs who received ≥2 doses, SAb was reactive in 36% and >100 U/mL in 16%. In all, 14 (39%) required oxygen, 11 (31%) required ICU admission, 5 (14%) were mechanically ventilated, and 4 (11%) died (Table). Sotrovimab was given to 27 eligible KTRs at median DOI 2 (range 0-6). Of these, 8 (30%) required oxygen, 5 (19%) required ICU admission, 2 (7%) were mechanically ventilated, and 1 died (4%). KTRs receiving sotrovimab at DOI ≤3 vs >3 were less likely to require oxygen (p=0.01) or ICU admission (p=0.02). Sotrovimab was well tolerated with one associated adverse event (self-limiting diarrhea).

*Conclusions: KTRs remain at high risk for severe COVID-19. Sotrovimab administered early in the disease course is associated with a lower rate of severe COVID-19.

Outcomes of KTRs with COVID-19 overall and among those receiving sotrovimab by day of illness
Outcomes N(%) Overall (N=36KTRs) Sotrovimab administered day 1-3 of illness (N=20) Sotrovimiab administered day 4+ of illness (N=7)
Any oxygen supplementation 14 (39%) 3 (15%) 5 (71%)
ICU admission 11 (31%) 2 (10%) 3 (43%)
Mortality, any cause 4 (11%) 0 1 (14%)
  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

D'Costa MR, Sran HK, Wong E, Chang Z, Chua Y, Somani J, Lum L, Vathsala A. Outcomes of Kidney Transplant Recipients with Covid-19 in Singapore Treated with Sotrovimab in the Era of the Delta Variant [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/outcomes-of-kidney-transplant-recipients-with-covid-19-in-singapore-treated-with-sotrovimab-in-the-era-of-the-delta-variant/. Accessed May 9, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences